Loading
A phase 2/3 trial of Fianlimab, Cemiplimab in non-small-cell lung cancer and small-cell lung cancer, run by Regeneron Pharmaceuticals, active and no longer recruiting.
A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC) is a phase 2/3 interventional study registered as NCT05785767 by Regeneron Pharmaceuticals, with 149 participants enrolled, started 2023-06-30 and due to reach its primary completion in 2027-09-28. Interventions recorded: fianlimab, cemiplimab, Placebo. Conditions listed: Advanced Non-Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Shares Regeneron, PD-L1-high non-small-cell lung cancer without a driver mutation, Cemiplimab, Small-cell lung cancer.
Shares Fianlimab, Regeneron, Cemiplimab, Immune checkpoint inhibitors.
Shares Fianlimab, Regeneron, Cemiplimab, Small-cell lung cancer.
Shares Fianlimab, Regeneron, Cemiplimab, Immune checkpoint inhibitors.
Shares Fianlimab, Regeneron, Cemiplimab, Small-cell lung cancer.
Shares PD-L1-high non-small-cell lung cancer without a driver mutation, Cemiplimab, Small-cell lung cancer, Immune checkpoint inhibitors.
Shares Fianlimab, Regeneron, Cemiplimab, Immune checkpoint inhibitors.
Shares Fianlimab, Regeneron, Cemiplimab, Immune checkpoint inhibitors.